Comparison between Sancode Technologies IPO and Sotac Pharmaceuticals IPO.
Sancode Technologies IPO is a SME Bookbuilding IPO proposed to list at BSE SME while Sotac Pharmaceuticals IPO is a SME Bookbuilding proposed to list at NSE SME.
| Sancode Technologies IPO | Sotac Pharmaceuticals IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Fixed Price | Bookbuilding |
| Listing At | BSE SME | NSE SME |
| Lead Managers | Shreni Shares Ltd. | Beeline Capital Advisors Pvt.Ltd. |
| Registrar | Bigshare Services Pvt.Ltd. | Kfin Technologies Ltd. |
| Market Maker | Shreni Shares Ltd. | Sunflower Broking Pvt.Ltd. |
| DRHP | DRHP  | DRHP |
| RHP | RHP | RHP |
| Anchor Investor | Anchor Investor | |
| IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Sancode Technologies IPO is up to ₹4.88 Cr whereas the issue size of the Sotac Pharmaceuticals IPO is up to ₹31.64 Cr. The final issue price of Sancode Technologies IPO is ₹47.00 per share and of Sotac Pharmaceuticals IPO is ₹111.00 per share.
| Sancode Technologies IPO | Sotac Pharmaceuticals IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹105.00 per share | |
| Issue Price (Upper) | ₹111.00 per share | |
| Issue Price (Final) | ₹47.00 per share | ₹111.00 per share |
| Discount (Retail) | ₹0.00 per share | ₹0.00 per share |
| Discount (Employee) | ||
| Market Lot Size | 3000 shares | 1200 shares |
| Fresh Issue Size | 10,38,000 shares | 28,50,000 shares |
| Fresh Issue Size (Amount) | up to ₹4.88 Cr | up to ₹31.64 Cr |
| OFS Issue Size | 0 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 10,38,000 shares | 28,50,000 shares |
| Issue Size Total (Amount) | up to ₹4.88 Cr | up to ₹31.64 Cr |
Sancode Technologies IPO opens on Mar 31, 2023, while Sotac Pharmaceuticals IPO opens on Mar 29, 2023. The closing date of Sancode Technologies IPO and Sotac Pharmaceuticals IPO is Apr 06, 2023, and Apr 03, 2023, respectively.
| Sancode Technologies IPO | Sotac Pharmaceuticals IPO | |
|---|---|---|
| Anchor Bid Date | Mar 28, 2023 | |
| Issue Open | Mar 31, 2023 | Mar 29, 2023 |
| Issue Close | Apr 06, 2023 | Apr 03, 2023 |
| Basis Of Allotment (Tentative) | Apr 12, 2023 | Apr 10, 2023 |
| Initiation of Refunds (Tentative) | Apr 13, 2023 | Apr 11, 2023 |
| Credit of Share (Tentative) | Apr 17, 2023 | Apr 12, 2023 |
| Listing date (Tentative) | Apr 18, 2023 | Apr 13, 2023 |
| Anchor Lockin End date 1 | May 10, 2023 | |
| Anchor Lockin End date 2 | Jul 09, 2023 |
Sancode Technologies IPO P/E ratio is 10.71, as compared to Sotac Pharmaceuticals IPO P/E ratio of 132.14.
| Sancode Technologies IPO | Sotac Pharmaceuticals IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 97.47 | 84.63 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 71.24 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 10.71 | 132.14 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹19.12 Cr. | ₹122.66 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 6.38% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 19.03% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 2.74 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Sancode Technologies IPO Retail Individual Investors (RII) are offered 5,19,000 shares while in Sotac Pharmaceuticals IPO retail investors are offered 5,19,000 shares. Qualified Institutional Buyers (QIB) are offered in Sancode Technologies IPO and 5,70,000 shares in Sotac Pharmaceuticals IPO.
| Sancode Technologies IPO | Sotac Pharmaceuticals IPO | |
|---|---|---|
| Anchor Investor Reserveration | 8,53,200 shares | |
| Market Maker Reserveration | 57,000 shares | 1,50,000 shares |
| QIB | 5,70,000 shares | |
| NII | 5,19,000 shares | 4,28,400 shares |
| RII | 5,19,000 shares | 9,98,400 shares |
| Employee | ||
| Others | ||
| Total | 10,38,000 shares | 28,50,000 shares |
Sancode Technologies IPO subscribed 3.68x in total, whereas Sotac Pharmaceuticals IPO subscribed 1.60x.
| Sancode Technologies IPO | Sotac Pharmaceuticals IPO | |
|---|---|---|
| QIB (times) | 1.00x | |
| NII (times) | 3.98x | 4.04x |
| Big NII (times) | ||
| Small NII (times) | ||
| RII (times) | 3.39x | 0.91x |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 3.68x | 1.60x |
Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
